RANKL: a promising target for cancer immunotherapy
Michael Herfs' team (Laboratory for Experimental Pathology) provides insight into the role of RANKL/RANK axis in immune tolerance and demonstrates the importance of blocking RANKL to reactivate anti-tumor immunity.
